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Abstract 37 
 38 
Background: 39 
 40 
Tuberculosis (TB) diagnosis in children is a major challenge with up to 94% of children with 41 
TB treated empirically in TB high-burden countries. Paediatric tuberculosis (PTB) remains a 42 
major cause of morbidity and mortality globally, particularly in developing countries. Most 43 
deaths/morbidity from TB in paediatrics could be prevented with early diagnosis and 44 
appropriate treatment. 45 
The main objective of this systematic review is to examine the evidence whether real-time 46 
polymerase chain reaction assay could be the most accurate clinical laboratory diagnostic 47 
methodology for the Mycobacterium tuberculosis (MTB) detection in paediatrics. 48 
 49 
   50 
Methods:  51 
 52 
We will search MEDLINE/PubMed, EMBASE, BIOSIS, LILACS, Cochrane Infectious Diseases 53 
Group Specialised Register (CIDG SR), Global Health and CINAHL for published studies that 54 
recruited children less than 16 years of age being investigated for Mycobacterium 55 
tuberculosis (MTB) infection using real-time polymerase chain reaction assay accompanied 56 
by mycobacteriological culture investigation as the reference standard. There will be no 57 
restriction regarding the language, date of publication and publication status.  We will 58 
include randomized controlled trials, observational studies (cohort, cross- sectional) in the 59 
review. 60 
 61 
Selection of studies, data extraction and management, assessment of risk of bias and quality 62 
of evidence will be performed by two independent reviewers (EB & BC). A third researcher 63 
will be consulted in case of discrepancies. Depending on the availability and quality of the 64 
data, a meta-analysis will be performed. Otherwise, findings will be qualitatively reported. 65 
 66 
Discussion:  67 
 68 
To our knowledge, this is the first systematic review and meta-analysis assessing the 69 
detection of MTB from all clinical samples’ types using real-time polymerase chain reaction 70 
assay in paediatric population. This review will make available evidence on the accuracy, 71 
approach and interpretation of results of this assay in the context of MTB diagnosis will 72 
meet an urgent need, considering the challenges of MTB diagnosis in paediatrics 73 
 74 
Systematic review registration: PROSPERO CRD42018104052 75 
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 78 
Background  79 
Tuberculosis (TB) diagnosis in children is a major challenge with up to 94% of children with 80 
TB treated empirically in TB high-burden countries. Diagnosis of pulmonary tuberculosis in 81 
children has relied predominantly on clinical, radiological, and tuberculin skin-test. TB in 82 
children is often missed or overlooked due to non-specific symptoms and or nonspecific 83 
diagnostic tests. [1, 2]. TB is an infectious disease caused by the bacillus Mycobacterium 84 
tuberculosis. It typically affects the lungs (pulmonary TB) but can also affect other sites 85 
(extrapulmonary TB). The disease is spread when people who are sick with pulmonary TB 86 
expel bacteria into the air, for example by coughing [2].  87 
At least 1 million children become ill with tuberculosis (TB) each year. Children represent 88 
about 10-11% of all TB cases. It is rarely bacteriologically confirmed [3]. Pulmonary TB is one 89 
of the top ten killers of children and infants worldwide. Young children are at particular risk 90 
of developing severe, often fatal or lifelong disabling forms of TB. In 2017, 233,000 children 91 
died of TB, among whom 52,000 were living with HIV [4,5]. 92 
 Paediatric tuberculosis (PTB) remains a major cause of morbidity and mortality globally, 93 
particularly in developing countries.  94 
Most deaths from PTB could be prevented with early diagnosis and appropriate treatment 95 
[6].  Generally, the lack of a simple and effective diagnostic test that can be utilised in 96 
resource-limited settings, where the infection is endemic, has hindered its control [7].  97 
The actual burden of TB in children is likely higher given the challenge in diagnosing 98 
childhood TB in many low-income countries where the diagnosis of paediatric TB is solely 99 
based on clinical evidence and smear microscopy [8]. 100 
 101 
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to 102 
stimulation by MTB antigens with no evidence of clinically manifest active TB [9]. The vast 103 
majority have no signs or symptoms of TB disease and are not infectious. Not all individuals 104 
infected with MTB develop active TB.  It is estimated that the lifetime risk of an individual 105 
with LTBI for progression to active TB disease is 5–10% over their lifetime [10]. The risk for 106 
active TB disease after infection depends on several factors, the most important being 107 
immunological status. This risk is particularly high among children under the age of 5 years 108 
[11].  109 
Tuberculin skin test (TST) or interferon-gamma release assay (IGRA) can be used to test for 110 
LTBI. As there is no “gold standard” test for LTBI [12]. It is only a marker of exposure, not 111 
disease [1]. 112 
 113 
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Establishing an accurate diagnosis of PTB in children can be more difficult than adult TB, 114 
because of the challenge children have in expectorating good-quality sputum or absence of 115 
lung parenchymal disease as in primary complex.  116 
This leads to a compromise of the quality of sputum smear microscopy results, with the 117 
added difficulty that the disease can be paucibacillary, with fewer organisms present in 118 
specimens. [13]. Culture systems which improve diagnosis take between 2-8 weeks in most 119 
cases [14, 15] 120 
Other diagnostic approaches are based on clinical presentations, radiographic 121 
abnormalities, contact history, tuberculin skin test, all of which are of low specificity [16]. 122 
 123 
The development of real-time polymerase chain reaction (RT-PCR)-based assays for the 124 
detection of Mycobacterium tuberculosis target genes (DNA) in clinical specimens has 125 
proved to be rapid and accurate. Since 2013, molecular tests have also been recommended 126 
for use in children and to diagnose specific forms of extrapulmonary TB. The assay has much 127 
better accuracy than sputum smear microscopy [17] 128 
 129 
This main objective of this systematic review is to synthesis the summary estimates whether 130 
RT- PCR assays will be more rapid, sensitive and specific for diagnosing MTB infection in 131 
paediatrics with tuberculosis compared to the culture-based assays. 132 
The outputs of this systematic review will serve as a resource for decision-makers, providing 133 
government stakeholders and healthcare practitioners with the tools to make evidence-134 
based decisions for PTB diagnosis and control. 135 
 136 
Research question  137 
Can real-time polymerase chain reaction (RT-PCR) assay be more rapid, sensitive and 138 
specific for routine detection of MTB from paediatrics samples in clinical microbiology 139 
laboratories compared to the culture-based assays (gold standard)? 140 
In answering this question, our study will address the following framework: Population, 141 
Index test, Comparison (Reference test), Outcome (PICO) question 142 
Methods:  143 
This systematic review protocol has been developed based on the Preferred Reporting Items 144 
for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines [18], which is 145 
available in Additional file 1. The systematic review protocol was registered with the 146 
International Prospective Register of Systematic Reviews (PROSPERO) database 147 
(Registration ID: CRD42018104052) 148 
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 149 
We will search MEDLINE/PubMed, EMBASE, BIOSIS, LILACS, Cochrane Infectious Diseases 150 
Group Specialised Register (CIDG SR), Global Health and CINAHL using the search strategy 151 
and terms used for one of the databases as detailed in Additional file 2. This will be used for 152 
published studies that recruited children less than 16 years of age being investigated for 153 
Mycobacterium tuberculosis (MTB) infection using real-time polymerase chain reaction 154 
assay accompanied by mycobacteriological culture investigation as the reference standard. 155 
There will be no restriction regarding the language, date of publication, and publication 156 
status. The search strategy for each database will be validated by a librarian information 157 
specialist familiar with the topic. The electronic search will be tailored for each database to 158 
include its specific keywords and MeSH terms.  159 
 160 
Searching other resources: 161 
To avoid missing relevant studies to be included, we will search other sources by looking 162 
through reference lists of relevant reviews and selected studies, searching websites of a 163 
relevant organization, searching of relevant articles using the PubMed related articles 164 
feature, Google Scholar, Cochrane Library, turning research into practice (TRIP), portal of 165 
the WHO International Clinical Trials Registry Platform (www.who.int/trialsearch) to identify 166 
ongoing trials, as well as StopTB Partnership’s New Diagnostics Working Group 167 
(www.stoptb.org/wg/new_diagnostics/), the World Health Organization and Centers for 168 
Disease Control and Prevention websites, proceedings of the International Union Against 169 
Tuberculosis and Lung disease (UNION) conference. We will also contact leading researchers 170 
at the Foundation for Innovative New Diagnostics (FIND). A search of grey literature 171 
including conference proceedings [Conference Proceedings Citation Index – Science (CPCI-172 
S)], Dissertations & Theses (www.proquest.com) and expert information will be done and 173 
added to our resource material . 174 
  175 
Data collection and analysis 176 
 177 
Study selection and data extraction 178 
After the literature search, two review authors (EB and BC) will independently screen 179 
studies for eligibility. Following screening, selection of studies irrespective of their design 180 
provided they meet the inclusion criteria will be carried out by two authors (EB & BC). They 181 
will independently review titles and abstracts against eligibility criteria to categorise as 182 
either “potentially include” or “exclude” (see Additional File 3, which is the Flow chart 183 
diagram). A third researcher (BO or GM) will be consulted in case of discrepancies at each of 184 
the stages. We will resolve differences in opinion through discussion.  We will list studies 185 
excluded after full-text assessment and their reasons for exclusion in a ‘Characteristics of 186 
excluded studies’ table. 187 
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 188 
Data will be extracted independently by EB & BC from each selected study using a 189 
predetermined list of categories/characteristics: first author, year of publication 190 
participants/population, index test, reference test, country, disease and target sequence 191 
gene for MTB DNA detection and results into a standardised data extraction form (see 192 
Additional file 4 Part A) 193 
 194 
We will conduct a risk of bias assessment at the level of the study using QUADAS-2 195 
(University of Bristol) tool that assesses diagnostic evaluation work in four domains: 1) 196 
patient selection, 2) the index test, 3) the reference standard and 4) patient flow and timing 197 
of tests (see Additional file 4 Part B). We will perform a narrative synthesis and depending 198 
on the availability and quality of the data a meta-analysis addressing our outcomes will be 199 
performed. For studies with missing or incomplete information for meta-analysis, we will 200 
contact the authors by using their contact information provided in the studies. When 201 
attempts to contact the authors have not been successful, such studies will be excluded 202 
from the meta-analysis. 203 
We will utilise the Review Manager (RevMan V5.3, Cochrane Collaboration, Oxford, UK) and 204 
Meta-DiSC (version 1.4) statistical software to carry out the meta-analysis [19,20]. For meta-205 
analysis, if there are enough studies, the bivariate model will be used because it takes into 206 
account potential threshold effects and the correlation between sensitivity and specificity. 207 
In addition, it will allow addition of covariates for investigation of potential sources of 208 
heterogeneity 209 
 We will also report point estimates and 95% confidence intervals, for sensitivity and 210 
specificity for each study as paired forest plots, and a plot summary receiver operating 211 
characteristics (SROC) curve [21], as different thresholds are expected to be used by 212 
manufacturers of RT-PCR assays.  213 
Subgroup analyses 214 
If a meta-analysis is carried out, subgroup analyses will be performed using the following a 215 
priori: 216 
1. Index test types and their respective target sequence genes: We will assess 217 
performance of different types of RT-PCR assays used for the detection of MTB from 218 
all the clinical specimen types and their respective target sequence genes.  219 
  220 
2. Type of reference test: The goal of a reference standard test is to provide error-free 221 
classification of the disease outcome presence or absence. We will assess the 222 
performance of mycobacteriology culture-based approaches in the following 223 
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regions: (1) studies using solid medium, (2) studies using liquid medium and (3) 224 
studies combining both media.  225 
 226 
3. TB Classification:  We will perform among the participants those who are having 227 
pulmonary tuberculosis versus those with extrapulmonary tuberculosis. 228 
 229 
4. Impact of RT-PCR assays on Low-and middle-income country (LMIC) versus High-230 
income country (HIC): We will assess sources of data to these graders.  231 
 232 
 Quality assessment: 233 
Two review authors (EB and BC) will independently conduct a risk of bias assessment at the 234 
level of the study using the QUADAS-2 (University of Bristol), the recommended tool for 235 
evaluating primary studies for the inclusion in systematic reviews for diagnostic accuracy.  236 
QUADAS-2 tool with assessment based on risk of bias and applicability of results has four 237 
domains evaluating (1) patient selection, (2) the index test, (3) the reference standard, and 238 
(4) patient flow and timing of tests (see Additional file 4 Part B)  239 
Assessment for heterogeneity and publication bias 240 
We will assess the extent of heterogeneity among studies visually with forest plots and 241 
SROC curves with 95% prediction regions and statistically with chi‐squared (χ2) and I‐242 
squared (I²) [21]. The source of heterogeneity will be investigated using stratified (subgroup) 243 
analyses. 244 
Every effort will be made to identify unpublished studies through searching conference 245 
abstracts, grey literature and reference lists of relevant primary articles to minimise 246 
publication bias. Formal assessment of publication bias using methods such as funnel plots 247 
or regression tests was not evaluated as this is not usually recommended in the meta-248 
analysis for diagnostic test accuracy [21]. 249 
Discussion:  250 
To our knowledge, this is the first systematic review and meta-analysis assessing the 251 
paediatric detection of MTB from all clinical samples’ types using real-time polymerase 252 
chain reaction assay. Pooling all available evidence on the accuracy, approach and 253 
interpretation of results of this assay in the context of MTB diagnosis will meet an urgent 254 
need, considering the challenges of MTB diagnosis in paediatrics. We therefore believe that 255 
our findings will have impact on policy and guide clinical laboratory practice to improve 256 
pediatric MTB diagnostic approach. The practicality of using RT-PCR assays in a resource-257 
limited setting will be discussed within the technical challenges, cost, reagents and other 258 
logistics. 259 
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Strengths and limitations of included studies and this review will be discussed, and 260 
recommendations for further research and clinical practice will be provided. 261 
 262 
Abbreviations:  263 
 264 
Conference Proceedings Citation Index – Science (CPCI-S); EMBASE: Excerpta Medica 265 
database; GRADE: Grades of Recommendation, Assessment, Development and Evaluation; 266 
HIC: High-income country; IGRA: Interferon-gamma release assay; LMIC: Low-and middle-267 
income country; LTBI: Latent tuberculosis infection; MEDLINE: Medical Literature Analysis 268 
and Retrieval System Online; MeSH: Medical Subject Headings; PRISMA: Preferred Reporting 269 
Items for Systematic Reviews and Meta-analysis; PRISMA-P: Preferred Reporting Items for 270 
Systematic Reviews and Meta-analysis Protocols; TRIP: Turning research into practice; TST: 271 
Tuberculin skin test; WHO ICTRP: WHO International Clinical Trials Registry Platform 272 
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